MONTANAPEP · RESEARCH LIBRARY
Peptide Research & Analytical Reference Library
An educational reference for research facilities, laboratory personnel, and scientific buyers, published by MontanaPep, also known as Montana Peptides. All MontanaPep products are sold exclusively for in-vitro laboratory research. This library covers how research peptides are manufactured, peptide chemistry, analytical testing, certificates of analysis, lyophilization, biologics and the published scientific literature.
What are peptides?
Peptides are chains of amino acids connected by peptide bonds. Depending on the convention used, shorter chains are generally described as peptides or oligopeptides, while longer chains can be described as polypeptides or proteins. NCBI describes peptides as compounds made from amino acids joined by peptide bonds in linear, branched, or cyclic structures.
The sequence, stereochemistry, terminal modifications, disulfide bonds, and other chemical modifications determine a peptide's molecular identity and properties.
What are biologics?
Biological products are a broad category that includes products such as vaccines, blood components, cells, gene therapies, tissues, and recombinant therapeutic proteins. FDA notes that biologics are often complex molecules or systems whose characterization and manufacturing can be more challenging than conventional small-molecule chemistry.
Not every research peptide is automatically a biologic under a particular regulatory definition. Classification depends on the molecule and applicable law.
What is lyophilization?
Lyophilization, commonly called freeze-drying, removes water from a frozen material under controlled vacuum conditions. The process generally involves freezing, primary drying by sublimation, and secondary drying to reduce residual moisture.
Freeze-drying is widely used in research and biopharmaceutical development because converting a peptide or protein formulation to a dry solid can improve storage stability compared with an aqueous formulation, although the process itself can affect aggregation or molecular conformation.
What is HPLC testing?
High-performance liquid chromatography (HPLC) separates chemical components as they pass through a chromatographic column. For peptide analysis, reverse-phase HPLC with UV detection is commonly used to assess chromatographic purity and generate a chromatogram showing the principal peak and related peaks.
HPLC purity is not the same thing as identity, net peptide content, sterility, endotoxin status, or heavy-metal testing. Those questions require appropriate analytical methods.
01How Research Peptides Are Manufactured
Inside an API production facility: synthesis, in-process control, purification and contamination control.
Nearly every research peptide on the market originates at an active pharmaceutical ingredient (API) production facility rather than at the company selling the vial. These are industrial pharmaceutical plants that produce bulk active substances by the kilogram. How that facility builds, purifies and controls the material says more about what is in a vial than any single headline number does, so this section describes the process in plain terms.
What an API production facility is
An API plant manufactures the active substance itself in bulk form — not tablets, not filled vials, not finished medicines. Its output is a purified powder, shipped with the manufacturer's own analytical release data for that lot.
The reference standard for how these plants are expected to operate is ICH Q7, the international good manufacturing practice guidance for active pharmaceutical ingredients, which the FDA has adopted as guidance and which underpins the equivalent requirements in the EU and China. It governs buildings and facilities, process equipment, documentation and records, materials management, production and in-process controls, validation, packaging, storage and distribution, and the handling of complaints and recalls.
Built one residue at a time
Most peptides in this catalog are made by solid-phase peptide synthesis. The first amino acid is anchored to an insoluble resin bead. The chain is then extended by repeating a cycle: remove the protecting group from the growing chain's end, couple the next protected amino acid using an activating reagent, then wash the resin thoroughly before the next cycle begins.
Those washes matter as much as the couplings. Excess reagent left behind from one cycle is what produces deletion and truncation impurities in the next, so removal of unreacted material is a control step in its own right, not housekeeping.
How each cycle is checked
Coupling completeness is monitored as the chain is built, using rapid colorimetric in-process tests — the Kaiser (ninhydrin) test and related methods — that detect unreacted amine groups and indicate whether a cycle went to completion before the next one starts.
Chromatographic in-process control is used as well, at defined checkpoints rather than after every single cycle, because assessing a solid-phase intermediate by HPLC requires cleaving a sample off the resin first. On a long chain the logic is cumulative: a 39-residue peptide means roughly 39 coupling cycles and 39 deprotections, and a small shortfall repeated across that many steps compounds. That is why control is designed into every cycle rather than left to a single test at the end.
Cleavage, purification and isolation
When the sequence is complete, the peptide is cleaved from the resin and its side-chain protecting groups are removed, usually with a strong acid cocktail, then precipitated. What comes off the resin is the target peptide together with the related substances generated along the way: deletion sequences missing a residue, truncated chains, epimers, and modified side products.
Purification is where those are separated out, typically by preparative reverse-phase HPLC, sometimes followed by a second chromatographic step working on a different separation principle for an orthogonal check. A salt-exchange step sets the counter-ion, and the purified material is lyophilized to a dry powder for stability in storage and shipment.
How contamination is controlled
- Segregation. Highly active or sensitizing compounds are handled in dedicated suites or dedicated equipment trains, so the material never shares a path with unrelated products.
- Campaign production. Where equipment is shared, one product is run as a campaign, then the line is fully cleaned and released before a different product is introduced.
- Classified air. Production areas run on filtered air with controlled pressure differentials, so air moves from cleaner space toward less clean space and not the reverse.
- Gowning and flow. Personnel, raw materials, in-process material and waste follow separate defined routes to keep incoming and outgoing streams from crossing.
- Single-use where practical. Disposable filters, liners, tubing and bags remove a changeover-cleaning risk entirely rather than managing it.
- Validated changeover. Cleaning between products is not judged by eye. Surfaces are swabbed and rinses are collected and analysed against pre-set carryover limits derived from toxicological exposure data for the previous compound.
Why more cleaning is not automatically better
Cleaning is validated rather than maximised, and the reason is that an over-aggressive procedure introduces its own problems.
- The cleaning agent itself becomes a residue. A detergent strong enough to strip the previous compound has to be shown to rinse away completely, and it is tested for on the same swab and rinse samples.
- Harsh chemistry and excessive cycle time degrade the passivated surface of stainless steel equipment, and a pitted or rouged surface holds residue more readily than an intact one — the opposite of the intended effect.
- Repeated aggressive cleaning generates particulates from gaskets, seals and hoses, adding a contamination source rather than removing one.
- An undocumented procedure that changes each time cannot be proven to work. A validated cleaning method is a defined, repeatable sequence demonstrated to reach a numerical limit, which is what makes the result reliable from one changeover to the next.
What the plant tests before the material ships
Release testing at an API facility is broader than the single purity percentage that circulates in the retail peptide market. A full release package for a synthetic peptide API generally covers identity by mass spectrometry and, where applicable, amino acid analysis; chromatographic purity with the individual related substances profiled rather than lumped together; net peptide content, which is the actual mass of peptide as distinct from chromatographic area percentage; water content by Karl Fischer; residual solvents; counter-ion content; and elemental impurities. Where the intended downstream use requires it, bioburden and bacterial endotoxin testing are added.
What this does and does not tell you. Manufacturing controls describe how a material was produced and how the plant establishes what it released. They are not a measurement of the individual vial in your hand, and no description of a production process should be read as one. A lot-specific analysis is the only thing that measures a specific lot, and independent verification is always available to a purchaser who wants it for their own records — the laboratories compared in the next section perform exactly that work, and none of them is affiliated with MontanaPep.
A note on certificates and Chinese manufacturing. A large share of the world's peptide API supply is produced in China, and claims about “GMP certification” there are frequently stated loosely. Since 1 December 2019, China's National Medical Products Administration no longer issues GMP certificates at all. Compliance is established through regulatory inspection of the facility, and the document available for exported product is a Certificate of a Pharmaceutical Product (CoPP), which attests to marketing status in China and to the manufacturer's history of GMP inspection. Anyone in this market presenting a current Chinese government GMP certificate as proof of anything is describing a document that has not been issued in years. The meaningful question about a plant is its inspection history, not a certificate.
Sources for this section: ICH Q7, Good Manufacturing Practice Guidance for Active Pharmaceutical Ingredients, as published by the U.S. Food and Drug Administration; the National Medical Products Administration's explanatory notes on GMP certificates and Certificates of a Pharmaceutical Product; and published industry accounts of control strategies for synthetic therapeutic peptide APIs, including manufacturing process considerations in Pharmaceutical Technology and Bachem's technical description of solid-phase peptide synthesis.
02Certificate of Analysis (COA) Guide
How to evaluate a research-lot analytical report.
What a strong COA should identify
- Exact compound name and, where applicable, CAS number.
- Manufacturer or submitting party and laboratory identity.
- Lot/batch number that matches the material being evaluated.
- Test date and report/accession number.
- Analytical method(s), not merely a headline purity percentage.
- Chromatogram or analytical output where appropriate.
- Identity result, typically supported by mass spectrometry or another validated identity method.
- Purity result and an explanation of how purity was calculated.
- Any separately ordered measurements such as net peptide content, endotoxin, residual solvents, heavy metals, or sterility.
How to read the numbers
- HPLC purity: usually an area-percentage measurement based on the chromatographic method. It does not automatically tell you the mass of peptide in the vial.
- LC-MS/MS: provides molecular-mass/identity evidence and can detect unexpected peptide species depending on the method and reference library.
- Net peptide content: attempts to quantify actual peptide material rather than simply reporting chromatographic area percentage.
- Endotoxin: measures bacterial lipopolysaccharide activity using an appropriate assay such as LAL. It is a separate analytical question from purity.
- Heavy metals: typically requires an elemental-analysis method such as ICP-MS.
- Sterility/microbial testing: requires microbiological methods and is not established by HPLC alone.
Important: A COA is evidence from a particular sample or lot under a particular method. A vendor-provided COA should be checked against the lot number and, where possible, independently verified. A high HPLC percentage by itself does not prove identity, concentration, sterility, endotoxin status, or absence of every possible contaminant.
03COA & Peptide Testing Laboratories
Every entry below was checked directly against the lab's own current website in September 2026. Prices and services can change; verify directly before ordering.
| Provider | Location | Core offering | Verified published price | Website |
|---|
| Freedom Diagnostics Testing | Franklin, TN, USA | HPLC + mass spectrometry purity/identity | Purity & ID reported at $200–225; net peptide content +$25; fentanyl screen +$40. Not posted as a public fee schedule — pricing comes through the intake form. | freedomdiagnosticstesting.com |
| Janoshik Analytical | Czech Republic (EU) | Compound-specific HPLC + mass-spec testing | BPC-157 test $215; add-ons: LC-MS screening +$205, endotoxin +$180, sterility +$290, heavy metals +$105, CHNS +$145. ~7 business day turnaround. Not ISO 17025 accredited. | janoshik.com |
| KMD Analytical | Chatsworth, CA, USA | RP-HPLC-UV identity + purity + net-peptide assay | $150/sample; $125 at 5+; $100 at 10+. Does not offer LC-MS, sterility, endotoxin, or heavy metals. | kmdanalytical.com |
| ACS Peptide Testing Labs | Sun City Center, FL, USA | HPLC purity + LC-MS identity, ISO 17025 accredited | Basic purity testing $150–300; identity + purity combination $400–600. 9–11 business day turnaround. | acslabtest.com |
| Prodigy Labs | San Diego, CA, USA | RP-HPLC purity / LC-MS identity, ISO/IEC 17025 accredited (specified scope) | Basic $195; LC-MS/MS identity $295; Sterility screening panel $750; full in-house USP <71> sterility release testing $1,195. | prodigy-labs.com |
| TrustPointe Analytics | Dorr, MI, USA | HPLC potency, purity & identity, founded by pharma-industry QC scientists | Per-compound assay pricing, e.g. BPC-157 $200. Not ISO 17025 accredited. 3–5 business day turnaround. | trustpointeanalytics.com |
| Axiom Analytics | USA | Defined multi-layer analytical panels (identity, purity, net content, Rapid DNA) | 4X Essential $195; 8X Comprehensive tier also offered. USP <71> sterility is a separate add-on. | axiomanalyticslab.com |
| Gold Standard Analytics | Franklin, TN, USA | HPLC + MS peptide panels with a published fee schedule | $189 base peptide COA; $289 GLP-1 class; endotoxin $199; sterility $195; heavy metals $169; volume discounts from 5 samples. | goldstandardanalytics.com |
| Finnrick | USA (US samples only) | Public crowdsourced testing & vendor-rating platform — not a lab itself | Free public testing for select products via a queue of several weeks, or an $89 expedited option (~10 business days) for some compounds. Uses independent partner laboratories; does not sell peptides. | finnrick.com |
Every figure above was checked directly against each lab's own current website in September 2026 (see the linked pages). None of these labs is affiliated with MontanaPep. Only ACS Peptide Testing Labs and Prodigy Labs (specified scope) carry ISO 17025 accreditation; the rest do not. A lab previously listed here, "Summit BioAnalytics," has been removed: no evidence could be found that an independent testing laboratory of that name exists, and it should not have been presented as a real, priced option.
04Individual Compound Research Reference Pages
One reference page per defined compound in the catalog, with structural identity, evidence models, and analytical notes.
This section distinguishes peptides from proteins, glycoproteins, small molecules, mixtures, and proprietary catalog names. Evidence labels describe where published research has been conducted; they do not represent a claim about a catalog sample.
Every product in the catalog has an interactive research reference available directly from its listing — tap the vial image or product name on any product card to open its Scientific Reference, Origins & History, Testing, and COA information.
05MontanaPep Products & Research Information
Search-friendly reference pages for MontanaPep products, peptide terminology, and analytical documentation.
MontanaPep is building a searchable research reference around its catalog. The goal is to make it easy for a research facility to find clear information about peptide structure, nomenclature, analytical testing, COAs, and published research literature. Product pages will identify the research-use-only nature of the catalog and link analytical documentation to the corresponding lot where available.
MontanaPep productspeptide products in Montanaresearch peptides MontanaHPLC peptide testingpeptide COAlyophilized peptidespeptide analytical testingresearch laboratory compounds